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Abstract 
As we embark on a new year of scientific inquiry in neurodegenerative disease research, it is helpful to take a 
look back and consider the contributions in the field with the potential to be the most impactful. The purpose 
of this review is to highlight recent advances in 2019 which have the potential to be transformative in the field 
of neurodegenerative neuropathology. Substantive scientific progress rarely occurs as a “eureka moment”, and 
when possible, we opted to highlight collaborative efforts and research trends. We also included groundbreak-
ing methodologies and tools. The generous increases in federal funding in the United States and elsewhere 
have massively expanded the total number of active programs researching Alzheimer’s disease. This exacer-
bates an imbalance, and an effort was made to highlight innovations across disease categories, and not to 
permit dementia to crowd out movement disorders, motor neuron disease, ataxias, etc. Thus, our overall goal 
was to highlight some of the most important discoveries, tools or methods that we feel will most likely directly 
enhance our ability to understand and diagnose neurodegenerative brain diseases. Given space limitations and 
the targeted readership of this journal, we selected ten topics most relevant to neuropathologists and clinical 
neuroscientists: 1. A new neurodegenerative disease category, 2. A new approach to probing gene expression 
on the single cell level, 3. A new approach merging histology and gene expression profiling, 4. A new computa-
tional approach using deep machine learning and computer vision, 5. A neuropathological substrate for sleep 
disturbance in Alzheimer’s disease, 6. A candidate pathogenic agent for Alzheimer’s disease, 7. A comprehen-
sive approach to morphometric analysis of cerebellar neurodegeneration, 8. The strongest evidence yet linking 
neurodegeneration to contact sports, 9. Mounting evidence for gut to central nervous system transmission in 
Parkinson’s disease, and 10. A spotlight on glia in Huntington’s disease. 
Keywords: Neurodegeneration, Neuropathology, Alzheimer’s disease, Limbic-predominant age-related TDP-43 encephalopathy, 
Amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease 
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1. LATE, a new old neurodegenerative 
disease 
As the population ages, researchers are gleaning 
fundamental new insights from the oldest-old popula-
tion (i.e., those over the age of 80 years) whose vulnera-
bility to neuropathology diverges from the younger-old. 
In a paper published in Brain, a large group of neuropa-
thologists led by Dr. Peter Nelson at the University of 
Kentucky introduced a new diagnostic category, limbic-
predominant age-related TDP-43 encephalopathy 
(LATE), describing a type of neurodegeneration that 
mostly strikes elderly individuals over 80 years old (Nel-
son et al., 2019). This work was the culmination of many 
years of study and a consensus group report, the goal of 
which was to address how to deal with the surprisingly 
large number of patients that variably develop an am-
nestic dementia that is very similar to that seen in Alz-
heimer’s disease (AD), but with abnormalities in the 
transactive response DNA binding protein of 43 kDa 
(TDP-43). 
Historically, the first study to recognize that there 
was something different occurring in these patients did 
so by identifying 13 autopsied subjects with dementia 
who had marked neuronal loss with reactive gliosis in 
the medial temporal lobe, but had no Alzheimer’s neu-
ropathological changes; this was termed “hippocampal 
sclerosis” (Dickson et al., 1994). This neuropathological 
signature is not specific, and it was not until TDP-43 was 
discovered in amyotrophic lateral sclerosis (ALS) and 
frontotemporal lobar degeneration (FTLD) patients that 
investigators thought to also look in hippocampal sclero-
sis patients and ultimately link the two. It was also rec-
ognized that subjects with TDP-43 proteinopathy only 
variably present with a pattern histologically considered 
hippocampal sclerosis on hematoxylin and eosin (H&E) 
stain 
Neuropathologically, subjects with LATE have the 
tell-tale abnormal translocation of TDP-43 from the 
nucleus to the cytoplasm, where it becomes phosphory-
lated (Figure 1). In LATE, TDP-43 pathology can be de-
tected in numerous brain regions, some of which over-
lap with FTLD, but the amygdala is most severely affect-
ed, followed by the hippocampal formation. Nelson et 
al. provided diagnostic criteria and a proposed hierar-
chical staging system for assessing patients for LATE 
neuropathologic change: TDP-43 immunohistochemistry 
is essential (hippocampal sclerosis pathology only is not 
sufficient) and should be performed in the amygdala 
(stage 1), mid-level hippocampus (stage 2) and middle 
frontal gyrus (stage 3). 
There is a great deal that we have to learn by stud-
ying LATE. While a few genes have been implicated as 
risk factors (i.e., APOE, GRN, TMEM106B, ABCC9, 
KCNMB2), larger genetic studies have the potential to 
better delineate mechanisms and causal pathways that 
could serve as biomarkers and therapeutic targets. Fur-
ther, we have very little understanding of the extent to 
which LATE affects non-Caucasian populations; studying 
more diverse populations has the potential to expand on 
risk factors, genetic and otherwise. Biochemical and 
molecular studies of TDP-43, including secondary modi-
fications such as phosphorylation, have the potential to 
lead to biomarkers that could be used pre-mortem. 
Finally, co-morbidities are nearly universal in the oldest-
old population, and the extent to which they interact 
with LATE pathology will be important for understanding 
its clinical significance. 
 
 
Figure 1. Limbic-predominant age-related TDP-43 encephalopathy (LATE). (A) LATE neuropathological change in an 83-year-old woman 
with dementia and the clinical diagnosis of AD. Marked atrophy and neuronal loss in the hippocampal formation, but with minimal AD 
neuropathological change. (B) TDP-43 proteinopathy is shown in the dentate gyrus. Image courtesy of Dr. Peter Nelson (NIH grant P30 
AG028383). 
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2. Single-cell transcriptomics 
Nothing has plagued molecular profiling of post-
mortem neurodegenerative disease brain tissue more 
than the problem of normalization in the context of 
variable and often massive neuronal loss with commen-
surate reactive gliosis. Numerous approaches have been 
developed to address this problem (e.g., deconvolution 
of bulk RNA sequencing or expression profiling of pooled 
cells isolated by laser capture microdissection), but they 
are laborious and results often fall short. Recent ad-
vances in high-throughput single cell sorting using micro-
fluidics coupled with next-generation sequencing have 
enabled a paradigm shift in how gene expression profiles 
can be investigated. The first papers deploying single-cell 
RNA sequencing (scRNA-seq) in human post-mortem 
neurodegenerative disease tissues have emerged in 
2019 and we expect this to transform transcriptomic 
studies (Del-Aguila et al., 2019; Grubman et al., 2019; 
Mathys et al., 2019). 
One of the major barriers that investigators en-
countered in applying single cell technology to human 
post-mortem brain is that it is not possible to isolate 
single cells from frozen tissue given the membrane 
breakdown. Thus, scRNA-seq is currently best done from 
cells isolated from fresh brain tissue, and precludes 
using archival frozen banked brains. Previous work in 
animal models, however, has shown that single nuclei 
can withstand the freezing process and yield nuclear 
RNA profiles that can serve as a proxy for those generat-
ed from cytoplasmic RNA. Because of this, groups are 
focusing on this variant approach termed single nuclei 
RNA-seq (snRNA-seq, or just Nuc-Seq). 
 
 
Figure 2. Single-nuclei RNA-seq (snRNA-seq) brain expression browser. Cell type specific expression profiles can be shown using a 
publicly available interactive web-based resource (http://ngi.pub/snuclRNA-seq) 
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Three studies were published in 2019 using Nuc-
Seq in post-mortem human brain tissue from patients 
with neurodegenerative disease. In the first, published 
online in August by Del-Aguila et al, investigators at 
Washington University in Saint Louis used Nuc-Seq to 
profile a patient with the PSEN1 p.A79V mutation and 
compared it to two related family members with sporad-
ic AD (non-mutational), and proposed a collection of 
best practices (Del-Aguila et al., 2019). All of these stud-
ies have made the data available online (Figure 2). In 
November, Grubman et al., from Monash University 
(Australia) and Duke-National University of Singapore 
Medical School, examined the entorhinal cortex from 6 
sporadic patients and 6 controls. Their group found that 
AD is associated with downregulation of APOE in oli-
godendrocyte precursors and astrocytes, and with up-
regulation of APOE in a subpopulation of microglia. They 
also explored transcription factor regulatory modules 
(Grubman et al., 2019). Finally, in the largest study pub-
lished in June by Mathys et al., investigators at the Broad 
Institute of MIT/Harvard profiled the prefrontal cortex 
from 48 individuals from the Rush ROSMAP cohort and 
identified sex differences in disease-associated subpopu-
lations of cells, and found interesting recurrent differ-
ences in myelination that might play a role in AD (Math-
ys et al., 2019). Together, these results are the first step 
towards providing a highly detailed cell-type specific 
molecular atlas of neurodegenerative diseases. 
3. Spatial transcriptomics 
Essentially all approaches to measuring gene ex-
pression are limited by the fact that isolation of nucleic 
acids from tissue by necessity disrupts the spatial rela-
tionship of the cells of interest. Losing the cellular archi-
tecture is a major barrier to understanding the context 
of genome-wide changes in RNA expression. This year 
we saw the first use of spatial transcriptomics, a method 
first introduced in 2016 that bridges RNA-sequencing 
and histopathology by allowing researchers to generate 
thousands of gene expression profiles from a single 
histological section using a slide printed with an array of 
barcoded specialized mRNA-capturing probes (Ståhl et 
al., 2016). 
 
 
Figure 3. Identification of expression programs using spatially resolved transcriptomics. (A) Example data for a single gene from Spa-
tial Transcriptomics profiling of postmortem lumbar and cervical spinal cord sections from a sporadic ALS patient presenting with bulbar 
symptom onset. (B) Data from many Spatial Transcriptomics arrays were aligned to a common coordinate system, and expression levels 
were hex binned spatially. This procedure enables reconstruction of larger regions than can be profiled with a single array and reveals 
expected spatial expression patterns for genes expressed by cell types present in specific tissue domains. (C) Spatially resolved coex-
pression analysis reveals gene sets with tissue domain specific expression patterns, a subset of which also exhibit differences with re-
spect to proximity to the site of symptom onset. Figure courtesy of Drs. Hemali Phatnani and Silas Maniatis. 
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In a study led by Hemali Phatnani at the New York 
Genome Center and published in Science (Maniatis et al., 
2019), spatial transcriptomics was applied to post-
mortem human amyotrophic lateral sclerosis tissue from 
seven patients with either lumbar- or bulbar-onset spo-
radic ALS (Figure 3). They also profiled SOD1-G93A 
transgenic mice. Together, they quantitated the spatial 
distribution of 11,138 mouse and 9624 human genes in 
spinal cord sections and confirmed the alteration in 
expression of some known ALS genes. They were also 
able to identify an abnormal microglial signature that 
preceded astroglial dysfunction. They chose to follow up 
on a mechanism involving TREM2 and its partner TY-
ROBP, revealing a spatiotemporal ordering with TYROBP 
expression upregulated pre-symptomatically before 
TREM2. Changes in other genes that are part of this 
mechanism (e.g., APOE, CX3CR1, LPL, B2M and CX3CR1) 
occurred later. These results demonstrate how this 
technology can lead to novel insights by being deployed 
as part of an interdisciplinary approach to neurodegen-
erative disease. 
4. Artificial intelligence and computer 
vision 
Since Alois Alzheimer first described the disease 
that bears his name in 1906, revealing striking morpho-
logical changes using ammoniacal silver stains, there has 
been very little progress in the way these cellular chang-
es are interpreted. Visual microscopic examination re-
mains state-of-the-art, but it is slow, imprecise, margin-
ally reproducible and requires the experience of a highly 
trained neuropathologist, the numbers of which are 
dwindling. The task is highly repetitive and fatigue induc-
ing, which increases the likelihood of error. The whole 
process would be best suited to automation, but the 
concept of a machine that could substitute for a neuro-
pathologist seemed implausible until recent develop-
ments in the field of artificial intelligence. Increases in 
computational power combined with improved algo-
rithms for training artificial neural networks have placed 
us at the precipice of a transformation moment in neu-
ropathology. The most common machine learning ap-
proach to analyzing visual imagery is the convolutional 
neural network (CNN). These are a type of deep learning, 
a class of artificial neural networks with multiple layers 
that progressively extract more complex features from 
the input. CNNs are based on the architecture of the 
organization of the animal visual cortex, encompassing 
simulations of overlapping receptive fields what were 
described by Hubel and Wiesel in the cat and monkey in 
the 1950s and 1960s. 
This year we saw the first two papers deploying 
deep learning to analyze digital whole slide images from 
patients with neurodegenerative diseases to identify 
both amyloid plaques and neurofibrillary tangles. One 
paper, published in Nature Communications and led by 
Dr. Brittany Dugger (University of California Davis), re-
ported a deep learning pipeline that identifies amyloid 
plaques and cerebral amyloid angiopathy in immuno-
histochemically stained slides (Tang et al., 2019). To 
build this, they annotated over 70,000 plaques that 
served as ground truth to train and evaluate the CNN 
achieving 0.993 receiver operating characteristic (ROC) 
curve and 0.743 precision recall curve. In another paper, 
investigators from the Center for Computational and 
Systems Pathology at the Icahn School of Medicine at 
Mount Sinai, led by Dr. John F. Crary (author of this re-
view) and published in Laboratory Investigation, focused 
on neurofibrillary tangle pathology (Signaevsky et al., 
2019). This study used 3177 images derived from pa-
tients with primary age-related tauopathy, chronic 
traumatic encephalopathy, progressive supranuclear 
palsy and Alzheimer’s disease to train and test the net-
work, achieving recall, precision and F1 scores of 0.91, 
0.80 and 0.85 respectively. We expect that this approach 
will be transformative in the near future with the devel-
opment of sophisticated neural networks capable of 
rapidly and reproducibly analyzing slides alongside, or 
perhaps instead of, the neuropathologist. In the long 
term, this will certainly transform the skillset of the neu-
ropathologist, who will perhaps be less adept at picking 
up subtle morphological features by eye, but hopefully 
more able to deploy computational and other modern 
tools. 
5. A neuropathological substrate for 
sleep-wake disruption in Alzheimer’s 
disease 
Sleep-wake disruption is common in aging and as-
sociated with cognitive decline and decreased quality of 
life. Sleep disturbance is seen in a number of neuro-
degenerative diseases and is amongst the earliest symp-
toms of AD. This includes reduced total, slow wave, and 
rapid eye movement (REM) sleep time. There are arous-
al deficiencies, including daytime sleepiness, that can 
precede cognitive impairment. Competition between 
subcortical populations of both wake promoting neurons 
(WPNs) and sleep promoting neurons (SPNs) provide a 
switch that coordinates sleep behaviors. Among these 
populations, WPNs in the locus coeruleus, orex-
in/hypocretin-producing neurons in the lateral hypotha-
lamic area, and histaminergic neurons in the tuber-
omammillary nucleus (TMN) play critical roles in 
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Figure 4. Tau pathology in the locus coeruleus in Alzheimer’s disease compared to progressive supranuclear palsy, corticobasal de-
generation and controls. Double-label immunohistochemistry showing colocalization of tau pathology (brown) and norepinephrine 
(red). Figure courtesy of Dr. Lea Grinberg. 
 
stimulating the cerebral cortex and contributing to 
arousal. The neuropathological substrate for sleep dis-
turbances in AD remains unclear, but attention has been 
focused on amyloid-beta (Aβ) as sleep promotes its 
clearance. Accumulation of abnormal hyperphosphory-
lated tau (p-tau), however, is a stronger correlate of 
neurodegeneration and functional decline, and accumu-
lation of p-tau in WPNs is among the first AD neuropa-
thological changes to appear in the brain. 
In a powerful study published in Alzheimer’s & 
Dementia, a team led by Dr. Lea Grinberg (UCSF) directly 
addressed the question of p-tau pathology in brainstem 
WPNs in AD by performing rigorous quantitative study, 
using stereological measures of wake-promoting cells in 
the locus coeruleus, lateral hypothalamic area and tu-
beromammillary nucleus in AD, compared to two amy-
loid-independent primary tauopathies (progressive su-
pranuclear palsy and corticobasal degeneration) and 
healthy controls (Oh et al., 2019). They found that while 
all three of these diseases displayed the presence of p-
tau in WPNs, only the AD patients exhibited clinically 
relevant cell loss (Figure 4). The implications are that 
loss of these cells are an important component of sleep 
disturbance in AD, but also that amyloid-independent 
tauopathies may benefit from alternative clinical ap-
proaches (e.g., suppression of the arousal system). 
6. Periodontal disease as a risk factor 
for Alzheimer’s disease 
Neuroinflammation is a well-recognized feature of 
AD, with activation of microglia, inflammasomes, and 
complement. Over the years, a number of infectious 
agents have been postulated to trigger this inflammation 
and participate in disease pathogenesis. The Aβ peptide 
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itself has even been demonstrated to have antimicrobial 
properties, supporting this hypothesis. One candidate 
pathogenic agent that has emerged is Porphyromonas 
gingivalis, a pathogen that plays a critical role as a key-
stone pathogen in chronic periodontitis (CP). Previously, 
among other supportive data, P. gingivalis was shown to 
be associated with cognitive decline in AD patients com-
pared to controls without CP. Furthermore, oral infec-
tion of Apoe-/- transgenic mice resulted in brain infec-
tion and complement activation. 
In a paper published in Science Advances, re-
searchers led by Drs. Jan Potempa (University of Louis-
ville) and Stephen S. Dominy (Cortexyme) have provided 
the strongest evidence yet that infiltration of the brain 
with P. gingivalis might be causal and that their toxicity 
is through their virulence factors termed gingipains 
(Dominy et al., 2019). Gingipains are secreted cysteine 
proteases that play critical roles related to host coloniza-
tion, inactivation of host defenses, iron/nutrient acquisi-
tion, and destruction of tissue. These researchers 
demonstrated the presence of gingipains in post-
mortem AD brain tissue alongside the presence of P. 
gingivalis DNA. Remarkably, treatment with a small 
molecule gingipain inhibitor blocks gingipain-induced 
neurodegeneration in an animal model with an associat-
ed decrease in host Aβ response to P. gingivalis. This 
orally available gingipain inhibitor is currently being 
tested in human clinical studies. More work needs to be 
done, and it is anticipated that this work might trigger a 
new research trend around periodontal disease in AD. 
7. Deconstructing cerebellar degener-
ation using “patholog-omics” 
Essential tremor (ET) is a common condition that 
can be associated with significant morbidity. For many 
years, the neuropathological features underlying ET had 
been a complete mystery, with autopsy studies being 
limited and qualitative. Recently, investigators have 
been building large cohorts of ET patients and a series of 
ET-related neuropathological changes have been report-
ed, but many had been observed in other neurodegen-
erative diseases affecting the cerebellum, raising ques-
tions of specificity. How these features and the other 
cerebellar degenerations are related had never been 
formally or systematically studied. 
In what could be considered a tour de force, inves-
tigators led by Drs. Elan Louis (Yale University) and Phyl-
lis Faust (Columbia University) published as landmark 
paper in Acta Neuropathologica applying what they 
termed a “patholog-omics” approach using 37 quantita-
tive morphological metrics (Louis et al., 2019). They 
compared 156 brains from healthy controls and patients 
with a spectrum of cerebellar diseases, including essen-
tial tremor, spinocerebellar ataxia, multiple system atro-
phy, Parkinson’s disease, and dystonia, mapping unique 
cellular patterns of neurodegeneration. Measures in-
cluded Purkinje cell loss, axonal changes (e.g., torpe-
does), basket cell hypertrophy, climbing fiber synaptic 
changes and others. They then used principal compo-
nent analysis to derive distinctive and overlapping signa-
tures marking each of these disorders. This study, which 
is the first of its kind to attempt to apply “omics” ap-
proaches to histomorphology, paves the way towards 
applying the approach to other neurodegenerative dis-
eases. 
8. Chronic traumatic encephalopathy 
and American football: a dose-
response relationship 
While the fact that repetitive mild traumatic brain 
injury leads to devastating long-term sequelae in profes-
sional boxers has been recognized for close to a century 
without controversy, chronic traumatic encephalopathy 
(CTE) only recently began to achieve substantial scien-
tific scrutiny and public interest when it was identified in 
American football players. While there is strong evi-
dence that repetitive head injuries are causal for CTE, 
skeptics remain. Among the criticisms is that while clini-
copathological studies are powerful, they are association 
analyses that ostensibly cannot prove a causal relation-
ship on their own. This is not the whole story. In 1965, 
Sir Austin Bradford Hill, an English statistician, proposed 
nine criteria that, when met, provide epidemiologic 
evidence of causality. In terms of CTE, eight of these 
criteria had been met, including strength (effect size), 
reproducibility, specificity, temporality, plausibility, co-
herence, experimentation and analogy. The missing 
criterion, until now, was evidence of a biological gradi-
ent: the presence of a dose-response relationship show-
ing that increased exposure leads to a greater inci-
dence/magnitude of the effect. 
In a report published online in November 2019 in 
the Annals of Neurology, researchers led by Drs. Jesse 
Mez and Ann C. McKee (Boston University) measured 
exposure to contact sports in the largest autopsy series 
of American football players ever assembled and calcu-
lated CTE risk. They found that the odds of CTE doubled 
with every 2.6 years of American football played (Mez et 
al., 2020). This paper firmly establishes that there is a 
dose-response relationship between exposure to Ameri-
can football and CTE, which the strongest indicator of 
causality obtainable. This study also provides hard data 
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for athletes and families trying to determine how much 
exposure might be considered safe. 
9. Parkinson’s disease: the gut-brain 
connection 
The pathological spread of abnormal protein ag-
gregates through “prion-like” templated misfolding is 
strongly implicated in a host of neurodegenerative dis-
eases. Parkinson’s disease is no exception, with rigorous 
neuroanatomical studies by Heiko Braak and colleagues 
describing a hierarchical spread of α-synuclein pathology 
caudally to rostrally in the central nervous system (Braak 
et al., 2003). Parkinson’s disease is notable in that it is 
not restricted to the central nervous system, with α-
synuclein aggregates present throughout the body in-
cluding the gastrointestinal tract. This, together with the 
fact that the dorsal motor nucleus of the vagus nerve, 
which heavily innervates the gut, is among the first re-
gions to show α-synuclein pathology, has fueled investi-
gation around whether Parkinson’s disease may be initi-
ated in the gut. This hypothesis is plausible given that a 
number of cohort studies of human subjects have a 
reduction in Parkinson’s disease risk following truncal 
vagotomy. Further, injection of various forms of human 
or recombinant α-synuclein fibrils into the gut at various 
sites leads to central pathology, but this pathology was 
minimal and transient (Holmqvist et al., 2014; Manfreds-
son et al., 2018; Uemura et al., 2018). 
Investigators at the Johns Hopkins University 
School of Medicine published a manuscript in Neuron 
showing results using a new experimental paradigm, 
which demonstrated severe and widespread α-synuclein 
pathology in the brains of transgenic mice following 
injection of preformed fibrils in the gut (Kim et al., 
2019). They injected α-synuclein fibrils directly into the 
muscularis layer of the duodenum and pylorus and 
tracked the progression of pathological aggregate gen-
eration to the dorsal motor nucleus, caudal hindbrain, 
and onward to the substantia nigra with accompanying 
cell loss and functional impairment. Truncal vagotomy 
blocked this spread, confirming the direct spread 
through this nerve, confirming what was seen previous-
ly. Further, knockout of α-synuclein prevented the 
spread as well, indicating that the propagation is de-
pendent on the molecule. This new animal model pro-
vides a robust experimental system, and together with 
the previous studies adds to the growing trend focusing 
on gut to brain transmission in Parkinson’s disease. 
10. Huntington’s disease: a spotlight 
on astrocytes 
Astrocytes play a critical role in a broad spectrum 
of nervous system functions, through direct interactions 
with neurons, blood vessels and other glial cell popula-
tions. Thus, it is not surprising that they have been im-
plicated in a number of neurodegenerative disorders. 
Glial pathology is well-documented in tauopathies (e.g., 
tufted astrocytes of PSP) and synucleinopathies (e.g., 
Papp-Lantos bodies in oligodendrocytes in MSA). Hun-
tington’s disease (HD) principally affects the striatum 
and cortico-striatal-thalamic circuitry with medium spiny 
neurons being most vulnerable. Intriguingly, the hun-
tingtin gene (HTT) gene is expressed in all cell types, but 
abnormalities in astrocytes have been demonstrated in 
post-mortem HD brains tissue. Astrocytes express mu-
tant HTT (mHTT) with increased GFAP expression and 
reactive changes. Reactive astrocytosis is a constant 
feature of neurodegeneration that accompanies neu-
ronal loss, but how these changes contribute to disease 
and the extent to which they are secondary changes or 
contribute causally is unclear. Emerging evidence from 
transcriptomic studies has begun to paint a picture sug-
gesting that astrocytes may not be passive bystanders, 
but may play an active role in some diseases, including 
HD. These studies have revealed two broad categories of 
astrocytes, termed A1 and A2, with A1 being neurotoxic 
(Liddelow et al., 2017; Zamanian et al., 2012). 
These and other studies prompted a group of in-
vestigators at UCLA, led by Dr. Baljit S. Khakh, to take a 
closer look at astrocytes in HD. Their study, published in 
October 2019 in Science Translational Medicine, used 
transcriptomic approaches in post-mortem human brain 
tissue from 36 Huntington’s disease patients, Vonsattel 
stage 0-3, alongside two transgenic mouse models to 
probe astrocyte pathology in HD (Diaz-Castro et al., 
2019). In their transgenic animals, they deployed a pow-
erful approach, termed RiboTag, which allowed them to 
specifically profile RNA expression in astrocytes. The 
result of this analysis was the elucidation of a novel core 
disease-associated astrocyte signature consisting of 62 
genes seen in both human post-mortem brain and the 
transgenic animals. Remarkably, alterations in this pro-
file could be ameliorated in their models using transcrip-
tional repression of the mHTT specifically in astrocytes 
using zinc finger protein (ZFP) transcriptional repressors. 
These findings are certain to accelerate the intensifica-
tion of interest in gliobiology in HD and other neuro-
degenerative disorders. 
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